AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visitors should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. —OR— The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). —OR— The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3843
Phone: 215/440-9300
FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1995 annual dues for active members are $160, $85 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1995) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti
Executive Director
### APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

**NAME OF CANDIDATE:**

<table>
<thead>
<tr>
<th>LAST</th>
<th>FIRST</th>
<th>M.I.</th>
</tr>
</thead>
</table>

**DATE OF BIRTH:**

**PRESENT POSITION/TITLE:**

**INSTITUTIONAL AFFILIATION:**

**INSTITUTIONAL ADDRESS:**

- **(City)***
- **(State/Province)***
- **(Country)***
- **(Postal Code)***

**TELEPHONE NUMBER:**

**FAX NUMBER:**

**E-MAIL NUMBER (CARRIER):**

**PRIMARY FIELD OF RESEARCH (Please check only one):**

- Biochemistry and Biophysics
- Biostatistics
- Cellular Biology and Genetics
- Clinical Investigations
- Carcinogenesis
- Epidemiology
- Immunology
- Molecular Biology and Genetics
- Preclinical Pharmacology and Experimental Therapeutics
- Virology
- Other:

**ACADEMIC DEGREES (Including where and when granted):**

**EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first):**

**PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.):**

<table>
<thead>
<tr>
<th>Candidate</th>
<th>Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOMINATED BY*:</td>
<td>SECONDED BY*:</td>
</tr>
<tr>
<td>(Please print)</td>
<td>(Please print)</td>
</tr>
</tbody>
</table>

**CANDIDATE IS APPLYING FOR (Check one):**

- [ ] ACTIVE
- [ ] CORRESPONDING
- [ ] MEMBERSHIP

**STATEMENT OF SUPPORT (in place of letters of recommendation):**

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

- How long has the candidate worked in the field of cancer research? _____ years
- Will the candidate make a long-term contribution to cancer research? Yes [ ] No [ ]
- Does the candidate's research adhere to accepted ethical standards? Yes [ ] No [ ]
- I therefore recommend this candidate for membership in the American Association for Cancer Research.

**Signature of nominator*:**

**Date**

**Signature of seconder*:**

**Date**

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)
GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association's high-quality journals Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates;
6. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1994 are $50 for associate members residing in the Americas and $40 for residents of other countries. For 1995 these rates are $35 and $45, respectively. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1994 have been set at $30 per year for residents of the Americas and $40 for residents of other countries. For 1995 these rates are $35 and $45, respectively. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in October 1994 for the forthcoming annual meeting must have paid dues for 1994. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1994 may retain associate membership until December 31, 1998. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti
Executive Director
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.
Public Ledger Building • Suite 816 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483

APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: _______________________________ DATE OF BIRTH: _______________________________

INSTITUTIONAL AFFILIATION: _______________________________

INSTITUTIONAL ADDRESS: _______________________________

(City) ___________________________ (State/Province) ___________________________ (Country) ___________________________ (Postal Code) ___________________________

TELEPHONE NUMBER: ___________________________ FAX NUMBER: ___________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): ___________________________

_____Graduate Student ___________________________ _____Medical Student ___________________________

_____Physician in Training ___________________________ _____Postdoctoral Fellow ___________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

_____Biochemistry and Biophysics ___________________________ _____Biostatistics ___________________________

_____Cellular Biology and Genetics ___________________________ _____Clinical Investigations ___________________________

_____Epidemiology ___________________________ _____Immunology ___________________________

_____Preclinical Pharmacology and Experimental Therapeutics ___________________________

_____Virology ___________________________ _____Other: ___________________________

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________

_________________________________________
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

- XyWrite III Plus (for the IBM)
- WordPerfect 4.2, 5.0, 5.1 (for the IBM)
- WordPerfect (for the Mac)
- Wordstar (for the IBM)
- Microsoft Word (for the IBM)
- Microsoft Word Macintosh (Versions 1–4) 400/800K
- Wang OIS (WPS)

Also acceptable:

- Apple II DOS 3.3
- Apple with Appleworks Software
- Apple III Plus DOS 3.3
- Apple Macintosh 400K Disc/
  MacWrite 2.2 (text)
- Apple Macintosh Plus 800K Disc/
  MacWrite 4.5 (text)
- CPT 8000
- DEC WPS-8
- DEC Decmate II
- DEC Decmate III
- Display Write 3
- IBM Displaywriter Word Processor 6580
- Lanier Business One Step
- Lanier No Problem
- Lanier Super No Problem
- MASS-11 PC
- Multimate
- PC Write
- PFS Professional Write
- Volkswriter 4.0

New releases of word processing software are not always immediately available for conversion. In addition, because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ___________________________________________
Name of computer used (e.g., IBM/PS2): _______________________________________
Operating system and version (e.g., DOS 3.3): ________________________________
Word processing program and version (e.g., WordPerfect 5.0): __________________
[See reverse for acceptable programs.]

Manuscript number: _______________________________________________________
First author: ______________________________________________________________
Corresponding author (if different from first author): ____________________________
Telephone/FAX numbers: ____________________________________________________

This form (both sides) may be reproduced.
THE FOLLOWING PROGRAMS ARE AVAILABLE ON VIDEO CASSETTE

EACH VIDEO PROGRAM CONSISTS OF ONE VIDEO, $39.00 UNLESS OTHERWISE NOTED

CAN 517V (2 cas, $58.00) Plenary Session: Integrated View of the Cancer Cell

CAN 529V Presidential Address: There's More Than One Way to Skin a Cat or Regulation of the Polycyclic Hydrocarbon-inducible Cytochrome P450IA1 Gene, Edward Bresnick; Presentation of the third Gertrude Elion Cancer Research Award

CAN 546V Fourth American Cancer Society Award Lecture: Inherited Susceptibility to Cancer: From Epidemiology to Interventional Research, Frederick P. Li

CAN 587V Fourteenth Cornelius P. Rhoads Memorial Award Lecture: Mapping Genes and Genomes: Genetic Dissection of Complex Traits, Eric S. Lander

CAN 5103V Fourteenth Bruce F. Cain Memorial Award Lecture: Initiatives with Platinum- and Quinazoline-based Antitumor Molecules, Kenneth R. Harrap

THE FOLLOWING PROGRAMS ARE AVAILABLE ON VIDEO CASSETTE

EACH VIDEO PROGRAM CONSISTS OF ONE VIDEO, $39.00 UNLESS OTHERWISE NOTED

CAN 517V (2 cas, $58.00) Plenary Session: Integrated View of the Cancer Cell

CAN 529V Presidential Address: There's More Than One Way to Skin a Cat or Regulation of the Polycyclic Hydrocarbon-inducible Cytochrome P450IA1 Gene, Edward Bresnick; Presentation of the third Gertrude Elion Cancer Research Award

CAN 546V Fourth American Cancer Society Award Lecture: Inherited Susceptibility to Cancer: From Epidemiology to Interventional Research, Frederick P. Li

CAN 587V Fourteenth Cornelius P. Rhoads Memorial Award Lecture: Mapping Genes and Genomes: Genetic Dissection of Complex Traits, Eric S. Lander

CAN 5103V Fourteenth Bruce F. Cain Memorial Award Lecture: Initiatives with Platinum- and Quinazoline-based Antitumor Molecules, Kenneth R. Harrap

PLEASE COMPLETE AND RETURN ENTIRE FORM

NAME

ORGANIZATION

ADDRESS (NO PO BOXES)

SIGNATURE

SEND TO: TEACH 'EM, 160 EAST ILLINOIS ST., CHICAGO, IL 60611
PHONE: (312) 467-0424 • FAX: (312) 467-9271 • TOLL-FREE: 1-800-223-3775

PHYSICIAN

VISA $25 MINIMUM ON CREDIT CARD ORDERS

MC

AMEX

EXPIRATION DATE

PLEASE NOTE: Any defective tapes will be replaced, but tapes are nonrefundable.

Please print in black ink only.

CAN 595 (2 cas, $23.00) Symposium 25: Human Gene Therapy in Clinical Cancer

CAN 596 (2 cas, $23.00) Symposium 26: Graft versus Tumor Effects

CAN 597 (3 cas, $34.50) Symposium Prevention 5: Chemoprevention: Inhibitors of the Arachidonic Acid Cascade

CAN 598 (3 cas, $34.50) Symposium Endocrinology 5: Prostate Cancer II

CAN 599 (3 cas, $34.50) Symposium Organ Site/Translational Session 7: Lung and Head and Neck Translational Research

CAN 5100 (3 cas, $34.50) Symposium Experimental Therapeutics 36: Novel Agents

CAN 5101 (3 cas, $34.50) Symposium Carcinogenesis 22: Human Genetics and Cancer Susceptibility

CAN 5102 (1 cas, $11.50) Controversy Session 5: Is Bone Marrow Transplantation Indicated for Breast Cancer?

CAN 5103 (1 cas, $11.50) Fourteenth Bruce F. Cain Memorial Award Lecture: Initiatives with Platinum- and Quinazoline-based Antitumor Molecules, Kenneth R. Harrap

CAN 5104 (1 cas, $11.50) Controversy Session 6: Are Estrogens Implicated in Breast Cancer?

CAN 5105 (3 cas, $34.50) Symposium Molecular Biology/Biochemistry 22: Regulation of Enzymes that Metabolize Drugs and Carcinogens

CAN 5106 (3 cas, $34.50) Symposium Immunology/Biological Therapy 12: Immunobiological and Therapeutic Aspects of Central Nervous System Tumors

CAN 5107 (3 cas, $34.50) Symposium Clinical Investigations 13: Hematopoietic Stem Cell Transplantation/High-Dose Chemotherapy

CAN 5108 (3 cas, $34.50) Symposium Carcinogenesis 26: Signal Transduction, Growth Factors, and Cellular Communication

CAN 5109 (3 cas, $34.50) Symposium Experimental Therapeutics 42: Drug Resistance: New Strategies and Targets

CAN 5110 (2 cas, $23.00) Symposium 27: Angiogenic Control of Tumor Growth

CAN 5111 (2 cas, $23.00) Symposium 28: Extracellular Matrix, Gene Expression and Cell Signaling

CAN 5112 (2 cas, $23.00) Symposium 29: Apoptosis

CAN 5113 (2 cas, $23.00) Symposium 30: Cancer Prevention and Intermediate Biomarkers
CANCER AND THE CELL CYCLE

Joint Conference of the American Association for Cancer Research and the Swiss Institute for Experimental Cancer Research

January 17-20, 1996
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland

CONFERENCE CHAIRPERSONS
Edward E. Harlow / Charlestown, MA
Viesturs Simanis / Lausanne, Switzerland

SCIENTIFIC PROGRAM

Introduction
Tim Hunt / London, England
J. Michael Bishop / San Francisco, CA

Control of CDKS
David Beach / Cold Spring Harbor, NY
Charles J. Sherr / Memphis, TN
Stephen J. Elledge / Houston, TX
James M. Roberts / Seattle, WA
Christian Lehner / Tübingen, Germany

Coordination of S Phase and M Phase
Matthias Peter / San Francisco, CA
Paul Nurse / London, England
Kim Nasmyth / Vienna, Austria
John Diffley / Herts, England

p53
Arnold J. Levine / Princeton, NJ
David P. Lane / Dundee, Scotland
Michael B. Kastan / Baltimore, MD
Eileen White / Piscataway, NJ
Richard Iggo / Epalinges, Switzerland

The Role of myc in Life and Death
Robert Eisenman / Seattle, WA
Gerard I. Evan / London, England
Martin Ellers / Heidelberg, Germany
Bruno Amati / Epalinges, Switzerland

G1 Progression in Higher Eukaryotes
Edward E. Harlow / Charlestown, MA
David M. Livingston / Boston, MA
Robert A. Weinberg / Cambridge, MA
Rene Bernards / Amsterdam, The Netherlands

Checkpoints
Andrew Murray / San Francisco, CA
Anthony Carr / Brighton, England
Ted A. Weinert / Tucson, AZ
Viesturs Simanis / Epalinges, Switzerland
Erich A. Nigg / Epalinges, Switzerland

Meeting Summary
Benjamin Lewin / Cambridge, MA

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: October 23, 1995

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
Clinical Cancer Research
An Official Journal of the American Association for Cancer Research

EDITOR-IN-CHIEF
John Mendelsohn
Chairman,
Department of Medicine
Memorial Sloan-Kettering Cancer Center

ASSOCIATE EDITORS
Martin D. Abeloff
David S. Alberts
Colin B. Begg
Joseph R. Bertino
Clara D. Bloomfield
George J. Bol
Michael C. Christian
Patricia Donahoe
Robert M. Elashoff
Isaiah J. Fidler
Stephen H. Freund
Philip D. Greenberg
Waun Ki Hong
Daniel C. Ihde
Lance A. Lipton
Marc E. Lippman
Michael T. Lotze
John D. Minna
Sharon B. Murphy
Richard J. O'Reilly
Ira Pastan
Herbert M. Pinedo
Jerome Ritz
Richard L. Schilsky
David Sidransky
Paul Sondel
Michael B. Sporn
Louise C. Strong
Jeffrey M. Trent
Daniel D. Von Hoff
Jane Weeks
Ralph R. Weichselbaum

SCOPE
Clinical Cancer Research, a new journal of the American Association for Cancer Research (AACR), publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

SPECIFIC AREAS OF INTEREST
CLINICAL AND TRANSLATIONAL RESEARCH IN:
- Molecular pharmacology and chemotherapy
- Drug sensitivity and resistance
- Tumor immunology and immunotherapy
- Radiobiology and radiation oncology
- Solid tumor oncology
- Hematological malignancies
- Surgical oncology
- Pediatric oncology
- Molecular oncology and cancer genes
- Pathology, markers, and prognostic indicators
- Growth factors, cytokines, and signal transduction
- Bone marrow transplantation
- Gene therapy
- Cancer endocrinology
- Cell adhesion, invasion, and metastasis
- Prevention of primary and recurrent cancer
- Differentiation and cell death
- Clinical genetics
- Detection of minimal disease

CALL FOR PAPERS
Submit manuscripts to:
John Mendelsohn, M.D., Editor-in-Chief
Clinical Cancer Research
Department of Medicine
Memorial Sloan-Kettering Cancer Center
1275 York Avenue, New York, NY 10021
Phone 212-639-6317; FAX 212-772-8375

CONTENTS
- Research articles
- Advances in Brief
- Controversies in Clinical Cancer Research
- Minireviews • Special invited articles
- Editorials • Letters to the Editor
- Meeting reports

ORDER TODAY!
Clinical Cancer Research
Vol. 1, 1995 (12 Issues), ISSN# 1078-0432
Telephone 1-800-875-2997; FAX 201-627-5872
- ACR member rate: Call 215-440-9300.
- Individual nonmember rate: $95
- For delivery outside U.S., add $20
- Institutional rate: $495*; Outside U.S. $575*
*Includes a subscription to Cancer Research
Available as a combined subscription only.
Canada: Add 7% GST, MB: Add state sales tax.